IMPACT OF LIPID-LOWERING THERAPIES ON TRIGLYCERIDE LEVELS IN US PATIENTS WITH ASCVD IN THE REAL-WORLD
Author(s)
Xinshuo Ma, MS1, Catherine Park, MHI1, Xiyuan Wu, MS2, Ting-ying jane HUANG, PhD3.
1Komodo Health, New York, NY, USA, 2Komodo Health, San Francisco, CA, USA, 3Director, Research Consulting, Komodo Health, New York, NY, USA.
1Komodo Health, New York, NY, USA, 2Komodo Health, San Francisco, CA, USA, 3Director, Research Consulting, Komodo Health, New York, NY, USA.
Presentation Documents
OBJECTIVES: Dyslipidemia is a significant risk factor to atherosclerotic cardiovascular disease (ASCVD). While treatments such as statins and ezetimibe are proven to lower LDL-C levels, evidence regarding their impact on triglyceride levels remains limited. This study evaluates changes in triglyceride levels among ASCVD patients in the United States.
METHODS: This retrospective cohort study used administrative data and claims from the Komodo Research Dataset and triglyceride results from the Komodo Laboratory Results from 1/1/2016 - 9/30/2025. Eligible patients were those aged over 18 years, diagnosed with ASCVD 6-month prior to their first ezetimibe/statin treatment (index date), continuously enrolled in medical and pharmacy plans during both 6-month pre-index and post-index periods. Patients with ≥1 triglyceride result in each period were further stratified to three groups based on treatments received within 6 months after the index date: 1) statin monotherapy 2) ezetimibe monotherapy 3) statin/ezetimibe combined therapy. A linear mixed model was built to assess the association between treatment and triglyceride level pre- and post-index.
RESULTS: A total of 2,752,295 statin monotherapy, 40,469 ezetimibe monotherapy, and 64,287 combined therapy users were identified, The mean age ranged from 64 (statin) to 69 (ezetimibe) years, with female composition varying from 39% (combined therapy) to 51% (ezetimibe). A greater triglycerides decrease during the 6-months post-index was observed in statin (19.3 mg/dL) users, followed by combotherapy (16.5 mg/dL) and ezetimibe (10.6 mg/dL) groups. The mixed model estimates showed an initial 30-day decrease in triglyceride levels across all groups (16.0 - 22.0 mg/dL reduction, p<0.001), thereafter, it remained stable in statin and slightly increased in ezetimibe users.
CONCLUSIONS: This real-world study suggests that both statin and ezetimibe therapies lower the triglycerides level after initial use and that standard lipid-lowering regimens may exhibit limited effectiveness in managing residual ASCVD risk associated with triglycerides.
METHODS: This retrospective cohort study used administrative data and claims from the Komodo Research Dataset and triglyceride results from the Komodo Laboratory Results from 1/1/2016 - 9/30/2025. Eligible patients were those aged over 18 years, diagnosed with ASCVD 6-month prior to their first ezetimibe/statin treatment (index date), continuously enrolled in medical and pharmacy plans during both 6-month pre-index and post-index periods. Patients with ≥1 triglyceride result in each period were further stratified to three groups based on treatments received within 6 months after the index date: 1) statin monotherapy 2) ezetimibe monotherapy 3) statin/ezetimibe combined therapy. A linear mixed model was built to assess the association between treatment and triglyceride level pre- and post-index.
RESULTS: A total of 2,752,295 statin monotherapy, 40,469 ezetimibe monotherapy, and 64,287 combined therapy users were identified, The mean age ranged from 64 (statin) to 69 (ezetimibe) years, with female composition varying from 39% (combined therapy) to 51% (ezetimibe). A greater triglycerides decrease during the 6-months post-index was observed in statin (19.3 mg/dL) users, followed by combotherapy (16.5 mg/dL) and ezetimibe (10.6 mg/dL) groups. The mixed model estimates showed an initial 30-day decrease in triglyceride levels across all groups (16.0 - 22.0 mg/dL reduction, p<0.001), thereafter, it remained stable in statin and slightly increased in ezetimibe users.
CONCLUSIONS: This real-world study suggests that both statin and ezetimibe therapies lower the triglycerides level after initial use and that standard lipid-lowering regimens may exhibit limited effectiveness in managing residual ASCVD risk associated with triglycerides.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO47
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)